GW0742

GW0742 is a selective agonist at PPAR-beta/delta, the same nuclear receptor GW501516 targets, from the same GlaxoSmithKline chemistry. It is sold in the research chemical market as the newer, cleaner cardarine.

The evidence does not support that framing in either direction. On benefit, the difference between the two compounds is stark: GW501516 has three published human trials, all of them measuring lipids over two to twelve weeks, while GW0742 has none at all. The endurance claim for GW0742 comes from a 2016 study in Balb/c mice treadmill-trained for four weeks, in which AICAR alone potentiated endurance and the combination of AICAR and GW0742 increased running time further, by 138 to 179 percent against exercised controls and 355 percent against non-exercised controls. Those are mouse running times, in a combination, not a GW0742 monotherapy result in a person.

On harm, the honest position is that the class-level cancer concern is real but unresolved, and part of the published record actually points the other way. GW501516 development stopped over rodent carcinogenicity findings that were never published as a primary paper. Meanwhile a Pennsylvania State group reported that both GW0742 and GW501516 failed to increase growth, Akt phosphorylation, VEGF or COX2 in five human cancer cell lines with or without serum, and that GW0742 attenuated rather than promoted chemically induced colon carcinogenesis in mice. So the literature contains a suppressed industrial safety finding on one side and published academic work finding no tumour promotion on the other.

No human has been given GW0742 in a published study of any design, so there is no human evidence section on this page. That absence is the most important fact about it, because it is sold next to GW501516 as though the two shared a record.

They do not. GW501516 was taken into people three times by its manufacturer, most substantially in a 268-person twelve-week lipid trial, and then abandoned when two-year rodent studies reportedly produced tumours in multiple organs. Those carcinogenicity studies were never published, which is why the site's cardarine page reports the anti-doping attestation rather than a citation. GW0742 inherited the class suspicion without inheriting any of the human safety experience, which is the worst of both positions.

The carcinogenicity question is genuinely contested in the published literature rather than settled. The Peters laboratory at Penn State published a series of studies finding no tumour promotion by either ligand in human cancer cell lines and an attenuation of chemically induced colon cancer in mice. That work is real and should be reported. It does not override an unpublished industrial two-year bioassay, and an unpublished bioassay does not override it either. Nobody can resolve this from the outside, which is itself a reason not to take the compound.